866-997-4948(US-Canada Toll Free)

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Nov 2017

Category :

Pharmaceutical

No. of Pages : 98 Pages

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Pipeline Review, H2 2017

Summary

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) pipeline Target constitutes close to 27 molecules. Out of which approximately 26 molecules are developed by companies and remaining by the universities/institutes. The latest report Tyrosine Protein Kinase SYK - Pipeline Review, H2 2017, outlays comprehensive information on the Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Spleen tyrosine kinase, also known as Syk, is an enzyme encoded by the SYK gene. It regulates several biological processes including innate and adaptive immunity, cell adhesion, osteoclast maturation, platelet activation and vascular development. It assembles into signaling complexes with activated receptors at the plasma membrane via interaction between its SH2 domains and the receptor tyrosine-phosphorylated ITAM domains. The association with the receptor can also be indirect and mediated by adapter proteins containing ITAM or partial hemITAM domains. The phosphorylation of the ITAM domains is generally mediated by SRC subfamily kinases upon engagement of the receptor. More rarely signal transduction via SYK could be ITAM-independent. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 8, 3, 10 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Immunology, Oncology, Dermatology, Gastrointestinal, Hematological Disorders, Ophthalmology, Respiratory, Cardiovascular, Central Nervous System, Genito Urinary System And Sex Hormones and Musculoskeletal Disorders which include indications Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, Rheumatoid Arthritis, Follicular Lymphoma, Waldenstrom Macroglobulinemia, Autoimmune Disorders, Peripheral T-Cell Lymphomas (PTCL), Allergic Conjunctivitis, Asthma, Atopic Dermatitis, B-Cell Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia (CLL), Cutaneous Lupus Erythematosus, Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), Marginal Zone B-cell Lymphoma, Non-Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL), Ulcerative Colitis, Acquired (Autoimmune) Hemolytic Anemia, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Allergies, Alzheimers Disease, Anaphylactic Shock, Arthritis, B-Cell Non-Hodgkin Lymphoma, Bladder Cancer, Blood Cancer, Chronic Urticaria Or Hives, Cutaneous T-Cell Lymphoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Glomerulonephritis, Graft Versus Host Disease (GVHD), Head And Neck Cancer Squamous Cell Carcinoma, Inflammation, Inflammatory Bowel Disease, Keratoconjunctivitis sicca (Dry Eye), Kidney Transplant Rejection, Lupus Nephritis, Metastatic Breast Cancer, Multiple Myeloma (Kahler Disease), Myelofibrosis, Non-Small Cell Lung Cancer, Peritoneal Cancer, Post-Transplant Lymphoproliferative Disorder, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Sicca Syndrome (Sjogren), Solid Tumor and Systemic Lupus Erythematosus.

Furthermore, this report also reviews key players involved in Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2)
- The report reviews Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Overview 8
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Therapeutics Development 9
Products under Development by Stage of Development 9
Products under Development by Therapy Area 10
Products under Development by Indication 11
Products under Development by Companies 15
Products under Development by Universities/Institutes 22
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Therapeutics Assessment 24
Assessment by Mechanism of Action 24
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Companies Involved in Therapeutics Development 28
AB Science SA 28
Almirall SA 28
Archer Pharmaceuticals Inc 29
Asana BioSciences LLC 29
Beijing Hanmi Pharmaceutical Co Ltd 29
Celgene Corp 30
Clevexel Pharma SAS 30
Fujifilm Corp 31
Genosco Inc 31
Gilead Sciences Inc 32
GlaxoSmithKline Plc 33
Hutchison MediPharma Ltd 34
Japan Tobacco Inc 34
Levolta Pharmaceuticals Inc 35
Merck KGaA 35
Millennium Pharmaceuticals Inc 36
Portola Pharmaceuticals Inc 36
Rigel Pharmaceuticals Inc 37
TopiVert Ltd 38
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Drug Profiles 39
AB-8779 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
ASN-002 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
C-13 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
CC-509 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
cerdulatinib - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
CVXL-0074 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
entospletinib - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
FF-10102 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
fostamatinib disodium - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
GS-492429 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
GS-9876 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
GSK-2646264 - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
HMPL-523 - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
JTE-852 - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
LAS-189386 - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
nilvadipine - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
PRT-2761 - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
SKIO-703 - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
Small Molecule to Inhibit SYK and JAK for Autoimmune Disorders and Oncology - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
Small Molecule to Inhibit SYK for Inflammation - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
Small Molecules to Inhibit Spleen Tyrosine Kinase for Immunology and Oncology - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
Small Molecules to Inhibit SYK for Diffuse Large B-Cell Lymphoma and Peripheral T-Cell Lymphoma - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
TAK-659 - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
TOP-1210 - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
TOP-1288 - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
TOP-1630 - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
TOP-1890 - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Dormant Products 85
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Discontinued Products 88
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Product Development Milestones 89
Featured News & Press Releases 89
Nov 01, 2017: Takeda to Present Data On TAK-659 During 59th ASH Annual Meeting 89
Oct 03, 2017: Fostamatinib Meets Pre-Specified Primary Endpoint in Stage 1 of Autoimmune Hemolytic Anemia Phase 2 Study 89
Oct 02, 2017: Rigel Provides Update on FDA Review of Fostamatinib for ITP 90
Jul 19, 2017: Onyx helps accelerate TopiVerts compound to clinic 90
Jul 19, 2017: TopiVert Provides Update on TOP1630 91
Jun 23, 2017: European Hematology Association: Two is better than one: The Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Rapid Tumor Responses in a Phase 2 Study for Relapsed/Refractory NHL 91
Jun 22, 2017: Rigel Announces Oral Presentation of TAVALISSE Phase 3 Clinical Data at the European Hematology Association 22nd Annual Congress 92
Jun 19, 2017: FDA Accepts Rigels New Drug Application for TAVALISSE (fostamatinib disodium) for the Treatment of Chronic ITP 93
Jun 15, 2017: Portola Pharmaceuticals Presents Interim Phase 2a Safety and Efficacy Data for Cerdulatinib at the International Congress of Malignant Lymphoma 93
May 30, 2017: Asana BioSciences Initiates Phase 2 Evaluation of ASN002, a Novel SYK/JAK Inhibitor, in NHL, CLL and MF 94
May 18, 2017: Portola Pharmaceuticals Announces Phase 2a Safety and Efficacy Cerdulatinib Data to be Presented at the European Hematology Association 94
May 09, 2017: Portola Pharmaceuticals Announces Cerdulatinib Data to be Presented at the International Conference on Malignant Lymphoma 95
Apr 27, 2017: Rigel Announces Tavalisse as Proprietary Name for Fostamatinib in the United States 95
Apr 17, 2017: Rigel Submits New Drug Application to FDA for Fostamatinib in Chronic ITP 96
Mar 27, 2017: Asana BioSciences To Present New Data on ASN002 at AACR 2017 96
Appendix 97
Methodology 97
Coverage 97
Secondary Research 97
Primary Research 97
Expert Panel Validation 97
Contact Us 97
Disclaimer 98

List of Tables
Number of Products under Development by Stage of Development, H2 2017 9
Number of Products under Development by Therapy Areas, H2 2017 10
Number of Products under Development by Indications, H2 2017 12
Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 13
Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017 14
Number of Products under Development by Companies, H2 2017 15
Products under Development by Companies, H2 2017 16
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 17
Products under Development by Companies, H2 2017 (Contd..2), H2 2017 18
Products under Development by Companies, H2 2017 (Contd..3), H2 2017 19
Products under Development by Companies, H2 2017 (Contd..4), H2 2017 20
Products under Development by Companies, H2 2017 (Contd..5), H2 2017 21
Number of Products under Investigation by Universities/Institutes, H2 2017 22
Products under Investigation by Universities/Institutes, H2 2017 23
Number of Products by Stage and Mechanism of Actions, H2 2017 24
Number of Products by Stage and Route of Administration, H2 2017 26
Number of Products by Stage and Molecule Type, H2 2017 27
Pipeline by AB Science SA, H2 2017 28
Pipeline by Almirall SA, H2 2017 28
Pipeline by Archer Pharmaceuticals Inc, H2 2017 29
Pipeline by Asana BioSciences LLC, H2 2017 29
Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H2 2017 30
Pipeline by Celgene Corp, H2 2017 30
Pipeline by Clevexel Pharma SAS, H2 2017 31
Pipeline by Fujifilm Corp, H2 2017 31
Pipeline by Genosco Inc, H2 2017 32
Pipeline by Gilead Sciences Inc, H2 2017 33
Pipeline by GlaxoSmithKline Plc, H2 2017 34
Pipeline by Hutchison MediPharma Ltd, H2 2017 34
Pipeline by Japan Tobacco Inc, H2 2017 35
Pipeline by Levolta Pharmaceuticals Inc, H2 2017 35
Pipeline by Merck KGaA, H2 2017 36
Pipeline by Millennium Pharmaceuticals Inc, H2 2017 36
Pipeline by Portola Pharmaceuticals Inc, H2 2017 37
Pipeline by Rigel Pharmaceuticals Inc, H2 2017 38
Pipeline by TopiVert Ltd, H2 2017 38
Dormant Products, H2 2017 85
Dormant Products, H2 2017 (Contd..1), H2 2017 86
Dormant Products, H2 2017 (Contd..2), H2 2017 87
Discontinued Products, H2 2017 88

List of Figures
Number of Products under Development by Stage of Development, H2 2017 9
Number of Products under Development by Therapy Areas, H2 2017 10
Number of Products under Development by Top 10 Indications, H2 2017 11
Number of Products by Stage and Mechanism of Actions, H2 2017 24
Number of Products by Routes of Administration, H2 2017 25
Number of Products by Stage and Routes of Administration, H2 2017 25
Number of Products by Stage and Molecule Type, H2 2017 27

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *